Latest 20-F annual reports

Cognyte Software Ltd. reported a significant increase in revenue and a return to operating profitability for the fiscal year ended January 31, 2026, alongside strategic updates and share repurchase authorizations.

Foresight Autonomous Holdings Ltd. reported an increased net loss for 2025 despite strategic partnerships and product advancements, raising going concern doubts.

Brenmiller Energy Ltd. reported a significant increase in net loss to $13.9 million in 2025, driven by higher operating losses and financial expenses, despite initial revenue generation from its thermal energy storage systems.

Nasus Pharma reports positive Phase 2 clinical results for its intranasal Epinephrine candidate, NS002, and successfully raises $15 million in a private placement, despite continued operating losses and going concern doubts.

Enlivex Therapeutics Ltd. reported a significant net income of $1.236 billion for 2025, primarily due to unrealized gains from its digital asset treasury, while advancing its Allocetra osteoarthritis therapy to Phase IIb.

Rentokil Initial reports a 4.4% revenue increase to $6.91 billion in 2025, but statutory profit declined, while strategic initiatives in North America show improving organic growth.

Millicom International Cellular S.A. reported a significant increase in net profit for 2025, driven by strategic acquisitions in Ecuador and Uruguay, tower infrastructure monetization, and operational efficiencies.

Titan America SA reports a robust 2025 with increased revenue and net income, a successful IPO, and strategic investments in sustainability and capacity expansion, despite identified internal control weaknesses.

Cadeler A/S reported a defining year in 2025, doubling its fleet capacity, achieving strong financial performance, and securing significant debt refinancing, while maintaining a robust order backlog.

Ucommune International Ltd. reported significant net losses and a shrinking operational footprint in 2025, raising substantial doubt about its ability to continue as a going concern while grappling with Nasdaq delisting warnings.

G. Willi-Food International Ltd. reported a significant increase in net income and revenues for fiscal year 2025, driven by improved product availability and commercial terms.

Vertical Aerospace Ltd. reported a net profit of £232.9 million for 2025, primarily driven by fair value gains on financial liabilities, while continuing to face significant capital requirements and going concern uncertainties for its eVTOL aircraft development.

Brazil Potash Corp. reports increased net losses and negative operating cash flows for 2025, continuing its pre-revenue development phase for the Autazes Potash Project in Brazil.

Abivax announced positive Phase 3 induction trial results for obefazimod in ulcerative colitis and significantly bolstered its financial position with a $747.5 million public offering, extending its cash runway into Q4 2027.

Chemomab Therapeutics Ltd. reported significant losses and a going concern warning, even as its lead drug nebokitug showed positive Phase 2 results for Primary Sclerosing Cholangitis and advanced to Phase 3 planning.

RYOJBABA Co., Ltd. reported a significant 91% decrease in net income for fiscal year 2025 to $119,394, despite completing an initial public offering and outlining strategic growth initiatives.

Eni reports flat net profit in 2025 despite declining crude oil prices, driven by strategic divestments and investments in new energy businesses.

HomesToLife Ltd announced significant revenue and net income growth in its 2025 annual report, driven by strategic acquisitions and international expansion.

BioLineRx Ltd. shifts strategic focus to oncology and rare diseases after out-licensing its approved drug APHEXDA, despite ongoing significant losses and a 'going concern' warning from management.

Lithium Argentina AG reported a net loss of $76.8 million for 2025, despite increased lithium carbonate production at Cauchari-Olaroz and significant progress on its Pozuelos-Pastos Grandes project.

Rubico Inc. reports a significant drop in net income for 2025, driven by increased finance costs and derivative losses, while strategically expanding its fleet with new tanker and yacht acquisitions.

SMX (Security Matters) Plc reported a substantial net loss of $174.59 million for 2025, alongside a significant board restructuring and an increased $250 million equity line of credit to address ongoing liquidity needs.

XORTX Therapeutics Inc. reported significant net losses for 2025, acquired a new renal therapeutic program, and received a Nasdaq delisting notice while also identifying a material weakness in internal controls.

Okeanis Eco Tankers Corp. reported increased profit for 2025, driven by reduced interest expenses and derivative gains, while actively refinancing debt and expanding its modern, eco-efficient tanker fleet.

Scorpio Tankers Inc. reported a 49% decrease in net income for 2025, driven by lower spot market rates and vessel sales, while strategically deleveraging and expanding its newbuilding fleet.

Telix Pharmaceuticals Limited filed an amendment to its 2025 annual report to correct exhibit hyperlinks and update executive certifications.

Cheer Holding, Inc. reports a slight revenue increase in 2025, driven by advertising, alongside significant investments in AI technology and plans for global expansion, despite ongoing regulatory uncertainties in China.

WORK Medical Technology Group LTD filed an amendment to its annual report to include auditor consents from WWC, P.C. and HTL International, LLC.

InflaRx N.V. reported a net loss of €45.6 million for 2025, shifting its strategic focus to the oral C5aR inhibitor izicopan after discontinuing active commercialization of GOHIBIC (vilobelimab) in the U.S. due to lack of commercial success.

Ermenegildo Zegna N.V. reports a slight revenue dip in 2025 amidst strategic wholesale streamlining and strong DTC growth, while leadership transitions to a new generation.